

REFERENCES

- Anonim. (2023, May 12). *Cost-Effectiveness Analysis*. U.S. Department of Veterans Affairs. <https://www.herc.research.va.gov/include/page.asp?id=cost-effectiveness-analysis#:~:text=The%20incremental%20cost%20effectiveness%20ratio,a%20cross%20different%20types%20of%20interventions.>
- Arbyn, M., Xu, L., Simoons, C., & Martin-Hirsch, P. P. (2018). Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. *Cochrane Database of Systematic Reviews*, 2020(5). <https://doi.org/10.1002/14651858.cd009069.pub3>
- BPJS Kesehatan. (2021). *Info BPJS Kesehatan: Penyakit Katastropik Berbiaya Mahal Tetap Dijamin Program JKN-KIS*. <https://bpjs-kesehatan.go.id/bpjs/dmdocuments/ae3544d7f3382ebb639eba99192b5c76.pdf>
- Brianti, P., Flammoneis, E. D., & Mercuri, S. R. (2017). Review of HPV-related diseases and cancers. *New Microbiologica*, 40(2), 80–85.
- Bruni, L., Albero, G., & Serrano, B. (2021). *Report HPV Infection in Indonesia.pdf*.
- Bruni, L., Albero, G., Serrano, B., Mena, M., & Collado, J. (2023). *Human Papillomavirus and Related Diseases Report: Indonesia*. HPV Information Centre.
- Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., Velandia-González, M., Pastore, R., Gacic-Dobo, M., & Bloem, P. (2021a). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. *Preventive Medicine*, 144, 106399. <https://doi.org/10.1016/j.ypmed.2020.106399>
- Bruni, L., Saura-Lázaro, A., Montoliu, A., Brotons, M., Alemany, L., Diallo, M. S., Afsar, O. Z., LaMontagne, D. S., Mosina, L., Contreras, M., Velandia-González, M., Pastore, R., Gacic-Dobo, M., & Bloem, P. (2021b). HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. *Preventive Medicine*, 144, 106399. <https://doi.org/10.1016/j.ypmed.2020.106399>
- Burbure, N., Handorf, E., Ridge, J. A., Bauman, J., Liu, J. C., Giri, A., & Galloway, T. J. (2021). Prognostic significance of HPV status and treatment modality in hypopharyngeal cancer. *Head & Neck*, 43(10), 3042–3052. <https://doi.org/10.1002/hed.26793>

- Cancer Registry. (2020, January). *Laporan Registrasi Kanker Berbasis Rumah Sakit periode Januari 2020 di RSUP Dr. Sardjito*. <https://canreg.fk.ugm.ac.id/laporan-data/registrasi-kanker-berbasis-rumah-sakit-dr-sardjito-fkkmk-ugm/januari-2020/>
- Cancers Associated with Human Papillomavirus (HPV)* | CDC. (2022, October 4). https://www.cdc.gov/cancer/hpv/basic_info/cancers.htm
- Chesson, H. W., Meites, E., Ekwueme, D. U., Saraiya, M., & Markowitz, L. E. (2020). Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model. *Vaccine*, 38(50), 8032–8039. <https://doi.org/10.1016/j.vaccine.2020.10.019>
- Cody, P., Tobe, K., Abe, M., & Elbasha, E. H. (2021). Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: A model-based study. *BMC Infectious Diseases*, 21(1), 11. <https://doi.org/10.1186/s12879-020-05632-0>
- Conway, E. L., Farmer, K. C., Lynch, W. J., Rees, G. L., Wain, G., & Adams, J. (2012). Quality of life valuations of HPV-associated cancer health states by the general population. *Sexually Transmitted Infections*, 88(7), 517–521. <https://doi.org/10.1136/sextrans-2011-050161>
- Couto, E., Sæterdal, I., Juvet, L. K., & Klemp, M. (2014). HPV catch-up vaccination of young women: A systematic review and meta-analysis. *BMC Public Health*, 14, 867. <https://doi.org/10.1186/1471-2458-14-867>
- Dahlstrom, K. R., Day, A. T., & Sturgis, E. M. (2021). Prevention and Screening of HPV Malignancies. *Seminars in Radiation Oncology*, 31(4), 297–308. <https://doi.org/10.1016/j.semradonc.2021.02.011>
- Daniels, V., Prabhu, V. S., Palmer, C., Samant, S., Kothari, S., Roberts, C., & Elbasha, E. (2021). Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States. *Human Vaccines & Immunotherapeutics*, 17(7), 1943–1951. <https://doi.org/10.1080/21645515.2020.1852870>
- De Martel, C., Georges, D., Bray, F., Ferlay, J., & Clifford, G. M. (2020). Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis. *The Lancet Global Health*, 8(2), e180–e190. [https://doi.org/10.1016/S2214-109X\(19\)30488-7](https://doi.org/10.1016/S2214-109X(19)30488-7)
- Demarteau, N., Van Krieking, G., & Simon, P. (2013). Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. *Vaccine*, 31(37), 3962–3971. <https://doi.org/10.1016/j.vaccine.2013.06.008>

- Dragicevic, D., Andjelic, B., Jovic, R. M., Kljajic, V., & Savovic, S. (2019). *Clinical stage of laryngeal carcinoma and lost time at the moment of diagnosis with 15-year-long interval. Are there any changes?* 24(5), 2041–2048.
- Geltzeiler, M., Bertolet, M., Albergotti, W., Gleysteen, J., Olson, B., Persky, M., Gross, N., Li, R., Andersen, P., Kim, S., Ferris, R. L., Duvvuri, U., & Clayburgh, D. (2018). Staging HPV-Related Oropharyngeal Cancer: Validation of AJCC-8 in a Surgical Cohort. *Oral Oncology*, 84, 82–87. <https://doi.org/10.1016/j.oraloncology.2018.07.013>
- Graham, D. M., Isaranuwachai, W., Habbous, S., de Oliveira, C., Liu, G., Siu, L. L., & Hoch, J. S. (2015). A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer: Male HPV Vaccination for OPC Prevention. *Cancer*, 121(11), 1785–1792. <https://doi.org/10.1002/cncr.29111>
- Health Technology Assessment (HTA) and Pharmacoeconomics Research Center. (2018). *POST-INTRODUCTION EVALUATION OF HPV VACCINE PROGRAMME IN INDONESIA*. Health Technology Assessment (HTA) and Pharmacoeconomics Research Center.
- Human Papillomavirus Infection—ClinicalKey*. (2022, May 18). ClinicalKey. https://www.clinicalkey.com/#!/content/clinical_overview/67-s2.0-3361f1dd-a7fd-414b-99b7-ec1706851397
- IARC, W. (2020). *Estimated age-standardized incidence rates (world) in 2020 ages 10-74*. Cancer Today International Agency for Research on Cancer. <http://gco.iarc.fr/today/home>
- Indonesian HTA Committee. (2017). *Health Technology Assessment (HTA) Guideline.pdf*.
- Janiak-Kiszka, J., Nowaczewska, M., & Kaźmierczak, W. (2022). Oral squamous cell carcinoma – clinical characteristics, treatment, and outcomes in a single institution retrospective cohort study. *Otolaryngologia Polska*, 76(3), 12–17. <https://doi.org/10.5604/01.3001.0015.7567>
- Kaderli, R., Schnüriger, B., & Brügger, L. E. (2014). The impact of smoking on HPV infection and the development of anogenital warts. *International Journal of Colorectal Disease*, 29(8), 899–908. <https://doi.org/10.1007/s00384-014-1922-y>
- Kamolratanakul, S., & Pitisuttithum, P. (2021). Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. *Vaccines*, 9(12), 1413. <https://doi.org/10.3390/vaccines9121413>

- Kazibwe, J., Gheorghe, A., Wilson, D., Ruiz, F., Chalkidou, K., & Chi, Y.-L. (2022). The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. *Value in Health*, 25(3), 385–389. <https://doi.org/10.1016/j.jval.2021.08.014>
- Kementerian Kesehatan Republik Indonesia. (2023). *Standar Tarif Pelayanan Kesehatan dalam Penyelenggaraan Jaminan Kesehatan* (Permenkes 3). <https://sehatnegeriku.kemkes.go.id/wp-content/uploads/2023/01/PERMENKES-NO-3-TAHUN-2023-TENTANG-STANDAR-TARIF-PELAYANAN-KESEHATAN-DALAM-PENYELENGGARAAN-JAMINAN-KESEHATAN-1.pdf>
- Ketua Tim Kerja Imunisasi Tambahan dan Khusus & Direktorat Pengelolaan Imunisasi. (2023). *Kebijakan Imunisasi Antigen Baru di Ind_8Nov23.pdf*. Kementerian Kesehatan Republik Indonesia.
- Kim, J. J., Simms, K. T., Killen, J., Smith, M. A., Burger, E. A., Sy, S., Regan, C., & Canfell, K. (2021). Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis. *PLoS Medicine*, 18(3), e1003534. <https://doi.org/10.1371/journal.pmed.1003534>
- Kombe Kombe, A. J., Li, B., Zahid, A., Mengist, H. M., Bounda, G.-A., Zhou, Y., & Jin, T. (2021). Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. *Frontiers in Public Health*, 8, 552028. <https://doi.org/10.3389/fpubh.2020.552028>
- Laprise, J.-F., Chesson, H. W., Markowitz, L. E., Drolet, M., Martin, D., B  nard,   ., & Brisson, M. (2020). Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States. *Annals of Internal Medicine*, 172(1), 22–29. <https://doi.org/10.7326/M19-1182>
- Lei, J., Ploner, A., Elfstr  m, K. M., Wang, J., Roth, A., Fang, F., Sundstr  m, K., Dillner, J., & Spar  n, P. (2020). HPV Vaccination and the Risk of Invasive Cervical Cancer. *New England Journal of Medicine*, 383(14), 1340–1348. <https://doi.org/10.1056/NEJMoa1917338>
- Linertov  , R., Guirado-Fuentes, C., Mar-Medina, J., & Teljeur, C. (2022). Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain. *Human Vaccines & Immunotherapeutics*, 18(6), 2127983. <https://doi.org/10.1080/21645515.2022.2127983>
- Liu, Y.-J., Zhang, Q., Hu, S.-Y., & Zhao, F.-H. (2016). Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical

cancer in China. *BMC Cancer*, 16, 164. <https://doi.org/10.1186/s12885-016-2207-3>

Luostarinen, T., Apter, D., Dillner, J., Eriksson, T., Harjula, K., Natunen, K., Paavonen, J., Pukkala, E., & Lehtinen, M. (2018). Vaccination protects against invasive HPV-associated cancers. *International Journal of Cancer*, 142(10), 2186–2187. <https://doi.org/10.1002/ijc.31231>

Markowitz, L. E., Dunne, E. F., Saraiya, M., & Chesson, H. W. (2014). *Human Papillomavirus Vaccination*. 63(5), 1–30.

Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019). *Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices*. 68(32).

Mousavi, A., Yousefnezhad, A., Modarres-Gilani, M., Akhavan, S., & Sheikh-Hasani, S. (2019). Vulvar cancer in Iran: Retrospective study over 20 years (1998-2018). *Journal of Family Medicine and Primary Care*, 8(4), 1465–1469. https://doi.org/10.4103/jfmpc.jfmpc_145_19

National Comprehensive Cancer Network. (2023). *NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma* (3.3023). https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf

Ndiaye, C., Mena, M., Alemany, L., Arbyn, M., Castellsagué, X., Laporte, L., Bosch, F. X., De Sanjosé, S., & Trottier, H. (2014). HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: A systematic review and meta-analysis. *The Lancet Oncology*, 15(12), 1319–1331. [https://doi.org/10.1016/S1470-2045\(14\)70471-1](https://doi.org/10.1016/S1470-2045(14)70471-1)

Ntanasis-Stathopoulos, I., Kyriazoglou, A., Lontos, M., & Gavriatopoulou, M. (2020). Current trends in the management and prevention of human papillomavirus (HPV) infection. *JBUON*, 25(3), 1281–1285.

Purba, F. D., Hunfeld, J. A. M., Iskandarsyah, A., Fitriana, T. S., Sadarjoen, S. S., Passchier, J., & Busschbach, J. J. V. (2018). Quality of life of the Indonesian general population: Test-retest reliability and population norms of the EQ-5D-5L and WHOQOL-BREF. *PLoS ONE*, 13(5), e0197098. <https://doi.org/10.1371/journal.pone.0197098>

Ren, X., Hao, Y., Wu, B., Jia, X., Niu, M., Wang, K., & Li, Z. (2022). Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: A meta-analysis. *Frontiers in Microbiology*, 13, 1052324. <https://doi.org/10.3389/fmicb.2022.1052324>

- Schwarze, R. (2015). *Systematic overview of cost-effectiveness thresholds in ten countries across four continents*. <https://doi.org/10.2217/cer.15.38>
- Setiawan, D., Andrijono, Hadinegoro, S. R., Meyta, H., Sitohang, R. V., Tandy, G., Perwitasari, D. A., & Postma, M. J. (2020). Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis. *PLOS ONE*, 15(3), e0230359. <https://doi.org/10.1371/journal.pone.0230359>
- Setiawan, D., Dolk, F. C., Suwantika, A. A., Westra, T. A., Wilschut, J. C., & Postma, M. J. (2016). Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia. *Value in Health Regional Issues*, 9, 84–92. <https://doi.org/10.1016/j.vhri.2015.10.010>
- Setiawan, D., Endarti, D., & Suwantika, A. A. (2017). *Farmakoekonomi Modeling* (2nd ed.). UMP Press.
- Setiawan, D., Luttjeboer, J., Pouwels, K. B., Wilschut, J. C., & Postma, M. J. (2017). Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: A meta-analysis. *Japanese Journal of Clinical Oncology*, jjco;hyw192v2. <https://doi.org/10.1093/jjco/hyw192>
- Shapiro, G. K. (2022). HPV Vaccination: An Underused Strategy for the Prevention of Cancer. *Current Oncology*, 29(5), 3780–3792. <https://doi.org/10.3390/currncol29050303>
- Simoens, S., Bento-Abreu, A., Merckx, B., Joubert, S., Vermeersch, S., Pavelyev, A., Varga, S., & Morais, E. (2021). Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium. *Frontiers in Pharmacology*, 12, 628434. <https://doi.org/10.3389/fphar.2021.628434>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
- Tarmidzi, S. N. (2023, November 15). *90 Persen Anak di Indonesia Ditargetkan Terlindungi dari HPV*. <https://www.kemkes.go.id/id/rilis-kesehatan/90-persen-anak-di-indonesia-ditargetkan-terlindungi-dari-hpv>
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., & Fernandez-Llimos, F. (2021). Principles of pharmacoeconomic analysis: The case of

pharmacist-led interventions. *Pharmacy Practice*, 19(1), 2302.
<https://doi.org/10.18549/PharmPract.2021.1.2302>

Types of Cancer. (n.d.). Cancer.Net. Retrieved August 16, 2023, from
<https://www.cancer.net/cancer-types>

Villa, A., Patton, L. L., Giuliano, A. R., Estrich, C. G., Pahlke, S. C., O'Brien, K. K., Lipman, R. D., & Araujo, M. W. B. (2020). Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines. *The Journal of the American Dental Association*, 151(4), 245-254.e24.
<https://doi.org/10.1016/j.adaj.2019.10.010>

Wolff, E., Elfström, K. M., Haugen Cange, H., Larsson, S., Englund, H., Sparén, P., & Roth, A. (2018). Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour. *Vaccine*, 36(34), 5160–5165. <https://doi.org/10.1016/j.vaccine.2018.07.018>

Wong, J., Allwright, M., Hruby, G., Roberts, J. M., Carr, A., Jin, F., Gett, R., Meagher, A. P., & Hillman, R. (2023). Anal cancer: A 20-year retrospective study from Australia. *ANZ Journal of Surgery*, 93(11), 2697–2705.
<https://doi.org/10.1111/ans.18586>

World Health Organization. (2019). *Global health estimates: Leading causes of death*. <https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death>

World Health Organization. (2023). *GHE: Life expectancy and healthy life expectancy*. The Global Health Observatory.
<https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-life-expectancy-and-healthy-life-expectancy>

Wu, X., Matanoski, G., Chen, V. W., Saraiya, M., Coughlin, S. S., King, J. B., & Tao, X.-G. (2008). Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. *Cancer*, 113(S10), 2873–2882. <https://doi.org/10.1002/cncr.23757>

Zou, K., Huang, Y., & Li, Z. (2022). Prevention and treatment of human papillomavirus in men benefits both men and women. *Frontiers in Cellular and Infection Microbiology*, 12, 1077651.
<https://doi.org/10.3389/fcimb.2022.1077651>